Early access: 15,547 bills from the current Congress so far, more added daily. Data from Congress.gov, GovInfo and the House and Senate vote records, updated Oct 13, 2026.
Public Law TrackerPLTPublic Law Tracker
S. 2296IntroducedSenateHouse · nowPresidentLawIn the House
Sec. 878 · S. 2296

Country-of-origin disclosure requirements for generic drugs purchased by the Department of Defense

Division A — Department of Defense authorizations › Title VIII — Acquisition policy, acquisition management, and related matters › Subtitle E — Other matters

Read this section in the full bill →

No wording changed between Committee version and Passed the Senate.

How the text changed

Before / AfterRedline
Committee version · Sec. 878

The Department of Defense may not procure for resale any generic drug unless the seller of such generic drug discloses the country the generic drug was manufactured in and the country of origin for all active pharmaceutical ingredients and key starting materials.

•S 2296 RSSEC. 878
Passed the Senate · Sec. 878

The Department of Defense may not procure for resale any generic drug unless the seller of such generic drug discloses the country the generic drug was manufactured in and the country of origin for all active pharmaceutical ingredients and key starting materials.

•S 2296 ESSEC. 878

added wordsremoved wordsComparison computed by Public Law Tracker from the official text